Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 55

1.

The role of regulatory T cells in cancer immunology.

Whiteside TL.

Immunotargets Ther. 2015 Aug 5;4:159-71. doi: 10.2147/ITT.S55415. eCollection 2015. Review.

2.

Targeted Therapies for the Treatment of Pediatric Non-Hodgkin Lymphomas: Present and Future.

Sorge CE, McDaniel JK, Xavier AC.

Pharmaceuticals (Basel). 2016 May 19;9(2). pii: E28. doi: 10.3390/ph9020028. Review.

3.

OX40, PD-1 and CTLA-4 are selectively expressed on tumor-infiltrating T cells in head and neck cancer.

Montler R, Bell RB, Thalhofer C, Leidner R, Feng Z, Fox BA, Cheng AC, Bui TG, Tucker C, Hoen H, Weinberg A.

Clin Transl Immunology. 2016 Apr 15;5(4):e70. doi: 10.1038/cti.2016.16. eCollection 2016 Apr.

4.

Induction of IL-25 secretion from tumour-associated fibroblasts suppresses mammary tumour metastasis.

Yin SY, Jian FY, Chen YH, Chien SC, Hsieh MC, Hsiao PW, Lee WH, Kuo YH, Yang NS.

Nat Commun. 2016 Apr 18;7:11311. doi: 10.1038/ncomms11311.

5.

To Infection and Beyond: The Multi-Pronged Anti-Cancer Mechanisms of Oncolytic Viruses.

Cassady KA, Haworth KB, Jackson J, Markert JM, Cripe TP.

Viruses. 2016 Feb 4;8(2). pii: E43. doi: 10.3390/v8020043. Review.

6.

Novel Drugs and Combination Therapies for the Treatment of Metastatic Melanoma.

Vennepureddy A, Thumallapally N, Motilal Nehru V, Atallah JP, Terjanian T.

J Clin Med Res. 2016 Feb;8(2):63-75. doi: 10.14740/jocmr2424w. Epub 2015 Dec 28. Review.

7.

Molecular Pathways: Targeting IDO1 and Other Tryptophan Dioxygenases for Cancer Immunotherapy.

Zhai L, Spranger S, Binder DC, Gritsina G, Lauing KL, Giles FJ, Wainwright DA.

Clin Cancer Res. 2015 Dec 15;21(24):5427-33. doi: 10.1158/1078-0432.CCR-15-0420. Epub 2015 Oct 30.

PMID:
26519060
8.

Human Cancer Immunotherapy with PD-1/PD-L1 Blockade.

Zheng P, Zhou Z.

Biomark Cancer. 2015 Sep 20;7(Suppl 2):15-8. doi: 10.4137/BIC.S29325. eCollection 2015. Review.

9.

Antitumor activity of epigenetic immunomodulation combined with CTLA-4 blockade in syngeneic mouse models.

Covre A, Coral S, Nicolay H, Parisi G, Fazio C, Colizzi F, Fratta E, Di Giacomo AM, Sigalotti L, Natali PG, Maio M.

Oncoimmunology. 2015 Apr 2;4(8):e1019978. eCollection 2015 Aug.

10.

Clinical impact of CD200 expression in patients with acute myeloid leukemia and correlation with other molecular prognostic factors.

Damiani D, Tiribelli M, Raspadori D, Sirianni S, Meneghel A, Cavalllin M, Michelutti A, Toffoletti E, Geromin A, Simeone E, Bocchia M, Fanin R.

Oncotarget. 2015 Oct 6;6(30):30212-21. doi: 10.18632/oncotarget.4901.

11.

The PD-1/B7-H1 pathway modulates the natural killer cells versus mouse glioma stem cells.

Huang BY, Zhan YP, Zong WJ, Yu CJ, Li JF, Qu YM, Han S.

PLoS One. 2015 Aug 12;10(8):e0134715. doi: 10.1371/journal.pone.0134715. eCollection 2015.

12.

Immunotherapy treatments for small-cell lung cancer: past, present and future.

Whitehurst M, Chiappori A.

Lung Cancer Manag. 2013;2(6):517-525.

13.

Novel immune checkpoint blocker approved for the treatment of advanced melanoma.

Galluzzi L, Kroemer G, Eggermont A.

Oncoimmunology. 2014 Dec 21;3(11):e967147. eCollection 2014 Nov. No abstract available.

14.
15.

Novel strategies for inhibiting PD-1 pathway-mediated immune suppression while simultaneously delivering activating signals to tumor-reactive T cells.

Ostrand-Rosenberg S, Horn LA, Alvarez JA.

Cancer Immunol Immunother. 2015 Oct;64(10):1287-93. doi: 10.1007/s00262-015-1677-5. Epub 2015 Mar 20. Review.

PMID:
25792524
16.

OX40 Agonists and Combination Immunotherapy: Putting the Pedal to the Metal.

Linch SN, McNamara MJ, Redmond WL.

Front Oncol. 2015 Feb 16;5:34. doi: 10.3389/fonc.2015.00034. eCollection 2015. Review.

PMID:
25763356
Free PMC Article
17.

The role of checkpoints in the treatment of GBM.

Kim JE, Lim M.

J Neurooncol. 2015 Jul;123(3):413-23. doi: 10.1007/s11060-015-1747-8. Epub 2015 Mar 7.

19.

Clinical trials of dendritic cell-based cancer vaccines in hematologic malignancies.

Pyzer AR, Avigan DE, Rosenblatt J.

Hum Vaccin Immunother. 2014;10(11):3125-31. doi: 10.4161/21645515.2014.982993. Review.

20.

CTLA-4 blockade with ipilimumab: biology, safety, efficacy, and future considerations.

Camacho LH.

Cancer Med. 2015 May;4(5):661-72. doi: 10.1002/cam4.371. Epub 2015 Jan 25. Review.

Items per page

Supplemental Content

Write to the Help Desk